Univariate analysis of factors associated with liver abnormalities in the matched case-control study in the PsA cohort.
| Variables | OR (95% CI) | p |
|---|---|---|
| Duration of psoriasis, yrs | 1.02 (1.01–1.04) | 0.005 |
| Duration of PsA, yrs | 1.08 (1.05–1.11) | < 0.0001 |
| Daily alcohol intake | 1.70 (0.78–3.71) | 0.18 |
| Employment | 0.34 (0.22–0.55) | < 0.0001 |
| PASI score | 1.01 (0.98–1.04) | 0.41 |
| Active (swollen or tender) joint count | 1.03 (0.99–1.06) | 0.06 |
| Clinically damaged joint count | 1.05 (1.02–1.07) | 0.0001 |
| ESR | 1.02 (1.00–1.03) | 0.03 |
| Elevated CRP | 1.27 (0.83–1.95) | 0.28 |
| Positive RF | 2.50 (0.49–12.89) | 0.27 |
| Positive ANA | 1.18 (0.67–2.09) | 0.56 |
| Hypertension | 3.33 (2.05–5.43) | < 0.0001 |
| Hyperlipidemia | 2.50 (1.45–4.32) | 0.001 |
| Diabetes | 1.64 (0.85–3.19) | 0.14 |
| BMI | 1.04 (1.00–1.09) | 0.04 |
| Use of NSAID | 0.63 (0.40–0.99) | 0.05 |
| Use of MTX/LEF | 1.28 (0.86–1.91) | 0.23 |
| Use of TNFi | 1.67 (1.08–2.57) | 0.02 |
PsA: psoriatic arthritis; PASI: Psoriasis Area and Severity Index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; ANA: antinuclear antibodies; BMI: body mass index; NSAID: nonsteroidal antiinflammatory drugs; MTX: methotrexate; LEF: leflunomide; TNFi: tumor necrosis factor inhibitors.